Select a State

Global health R&D delivers for Alabama

US government investment in global health R&D has delivered

$68.7 million
to Alabama research institutions
850+ new jobs
for Alabama

Neglected diseases in Alabama

Chikungunya cases
22
Dengue cases
39
HIV diagnoses
5,943
Malaria cases
66
Tuberculosis cases
1,257
West Nile cases
127
Zika cases
40

Alabama's top USG-funded global health R&D institutions

University of Alabama at Birmingham
$53.3 million
Southern Research Institute
$14.1 million
Auburn University
$876 thousand
Alabama State University
$341 thousand

Alabama industry in global health R&D

CNine Biosolutions
Location(s):
Birmingham
Biocryst Pharmaceuticals
Location(s):
Birmingham

Alabama's top areas of global health R&D by USG funding

61.6%
HIV/AIDS
2.4%
Malaria
21.7%
Tuberculosis
6.6%
Bacteria pneumonia & meningitis
3.4%
Neglected tropical diseases
Dengue
Kinetoplastids
Trachoma
4.2%
Other
Diarrheal diseases
Ebola/viral hemorrhagic fevers
Hepatitis C
Non-allocable
Rheumatic fever

Global health R&D at work in Alabama

The University of Alabama at Birmingham School of Medicine operates the Antiviral Drug Discovery and Development Center (AD3C), funded by the US National Institutes of Health. AD3C focuses on developing drug therapies for diseases such as influenza, West Nile virus, SARS, chikungunya, and dengue. Researchers work to target and inhibit enzymes essential for viral replication. The viruses AD3C targets are of high priority for the US government as the global burden of these diseases is enormous, with West Nile virus and influenza routinely infecting US citizens. Southern Research Institute in Birmingham is supporting AD3C in screening potential compounds.

Footnotes